Manufacturer:
Ardelyx
Route of Administration:
Oral
Site of Care:
Outpatient
Website:
phone:
877-527-3927
Approved Indication:
reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy
Conditions:
- Chronic Kidney Disease
Therapeutic Area:
- Nephrology